GLS and neoplasm: Promisingly, small molecule GLS inhibitors have been shown to exhibit anti-proliferative activity and reduce tumour burden [43,48,49] across a variety of tumours, including lymphoma, breast, pancreatic, non–small cell lung and renal cancers [9,10,48,50,51].